BREAKING NEWS: Anthos Therapeutics’ Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab, Demonstrated a 67% Greater Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding 
Compared to Rivaroxaban in Patients with Atrial Fibrillation

INVESTORS

Nicholas Galakatos

Sr. Managing Director, Blackstone;
Chairman of the Board of Directors, Anthos Therapeutics

Paris Panayiotopoulos

Sr. Managing Director, Blackstone;
Member of the Board of Directors, Anthos Therapeutics

Ari Brettman

Sr. Managing Director, Blackstone;
Member of the Board of Directors, Anthos Therapeutics

By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines that improve patients’ lives.